The estimated Net Worth of Christopher Flint O Brien is at least $18.8 Milión dollars as of 5 February 2018. Christopher Brien owns over 2,613 units of Neurocrine Biosciences stock worth over $6,597,036 and over the last 19 years Christopher sold NBIX stock worth over $12,168,593.
Christopher has made over 47 trades of the Neurocrine Biosciences stock since 2013, according to the Form 4 filled with the SEC. Most recently Christopher sold 2,613 units of NBIX stock worth $217,349 on 5 February 2018.
The largest trade Christopher's ever made was exercising 105,634 units of Neurocrine Biosciences stock on 18 May 2017 worth over $671,832. On average, Christopher trades about 11,263 units every 27 days since 2005. As of 5 February 2018 Christopher still owns at least 54,310 units of Neurocrine Biosciences stock.
You can see the complete history of Christopher Brien stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO, CA, 92130.
Over the last 21 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... a Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: